It’s no surprise really. We live in a world too often tainted by crime, lawsuits, swindling, cover-ups and terrorism.
It's no surprise really. We live in a world too often tainted by crime, lawsuits, swindling, cover-ups and terrorism. It's hard to know who to trust, so we just don'st at least not at face value anymore. We don'st trust until given a reason not to as we once did. We trust only after one's proven themselves worthy of that trust. A reversal from days past for better or worse.
The world's corporations are among the most distrusted institutions in our lives today. Again, no surprise really. The news is full of unethical behavior and shady business practices and that's only what we know about.
A recent (January 28, 2004) Health Care Poll from Harris Interactive indicates that while many Americans (44%) have a lot of trust in the drugs they take, far fewer (14%) trust the companies that make them.
Why is that? The pharma industry hasn'st been riddled with scandals of the likes of Enron and Worldcom. Why the intense distrust?
I would contend the public trusts the medicines, because they take them and they work. They improve their lives. They trust the science and the safety of the products, because the medicines go to work earning that trust in households across the world each and every day.
It's the business behind the medicines that feels, to most consumers, much like the unknown that lurks behind the black curtain of the great Wizard of Oz. Let's face it, we fear and distrust what we cannot see.
Perhaps the industry simply hasn'st revealed enough of its inner workings to adequately earn the public's trust. What lurks behind the manicured lawns and lights in the windows of pharma campuses is largely a mystery to most of our customers.
There is no easy answer. But maybe it's a matter of working hard to push the black curtain aside and help the public better understand complicated matters like R&D costs and effort and how that translates to retail drug prices. Perhaps open houses and public outreach events would give the communities we live and work in a glimpse of the inside of pharma.
It's time to demystify the industry and give consumers a basis for trusting more than our medicines.
blog comments powered by DisqusAndrew Tolve investigates the value of the Internet as a pharma marketing research medium
Often criticised for not properly adopting new web technologies, pharma proves it knows a thing or two about the corporate website.
Jan Stojaspal explores the role of value-based pricing in gaining market access
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs